Kangtai Biological: Quadrivalent Influenza Virus Split Vaccine Starts Phase I Clinical Trial

Kangtai Biological announced that the phase I clinical trial preparation for its quadrivalent influenza virus split vaccine has been completed, and the phase I clinical trial has commenced, successfully enrolling the first subject recently. This vaccine is suitable for individuals aged 6 to 35 months and can stimulate the body to produce immunity against influenza viruses, aimed at preventing influenza caused by vaccine-related strains. The phase I clinical trial for the quadrivalent influenza virus split vaccine is designed as a single-center, randomized, blind, positive-control study, aimed at evaluating the safety and preliminary immunogenicity of the vaccine in the 6 to 35-month age group